Abiraterone (NCT06378866)

Name: Abiraterone trial for Recurrent Castration-Sensitive Prostate Carcinoma (NCT06378866)
Uploaded: 2026-10-31T21:29:57.474Z
Duration: 1 min 18 s
Description: Abiraterone trial for Recurrent Castration-Sensitive Prostate Carcinoma (NCT06378866). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06378866.

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial: a one-minute explainerNCT063788661 min

Abiraterone trial for Recurrent Castration-Sensitive Prostate Carcinoma (NCT06378866). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult men with recurrent, non-castrate prostate cancer: either up to five metastases, including one beyond the pelvis, or rising PSA without recurrence visible on advanced imaging. Prior prostate chemotherapy or metastasis-directed treatment excludes participation.

The idea: focused radiation treats tumor sites; hormone treatments reduce androgen signaling. One randomized comparison tests radiation with or without six months of hormone treatment. Another compares salvage radiation against observation until imaging guides treatment. Researchers measure progression.

This phase 2 study plans 532 patients. Jacob Orme leads at Mayo Clinic; three US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.